Lupin Limited — Updates, 12-02-2025: Press Release

Lupin Limited reported solid Q3 FY2025 financial results, showcasing a 10.6% year-over-year sales increase to INR 56,186 Mn, driven by robust performance across key markets. EBITDA surged by 32.1%, reaching INR 14,096 Mn, while profit before tax (PBT) rose 45.5% to INR 10,713 Mn. Notably, the EBITDA margin improved to 25.1%, reflecting enhanced operational efficiency. The company made substantial investments in R&D, amounting to INR 4,344 Mn, or 7.7% of sales, signaling a commitment to innovation.

North America, a primary revenue driver, saw a 12.3% increase in sales to INR 21,213 Mn as Lupin maintained its status as a leading generic player. India revenues also grew by 11.9% to INR 19,305 Mn, bolstered by multiple new product launches. EMEA exhibited robust growth, spiking 20.9%. With a positive outlook backed by strategic investments and a solid market position, Lupin is well-equipped for continued growth in upcoming quarters. Investors may view these developments as indicators of strong operational momentum and market resilience.